Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.

ABSTRACT:

Background and aims

In patients with de novo heart failure with reduced ejection fraction (HFrEF), improvement of left ventricular ejection fraction (LVEF) is expected to occur when started on guideline-recommended medical therapy. However, improvement may not be completed within 90 days.

Methods

Patients with HFrEF and LVEF ≤ 35% prescribed a wearable cardioverter-defibrillator between 2017 and 2022 from 68 sites were enrolled, starting with a registry phase for 3 months and followed by a study phase up to 1 year. The primary endpoints were LVEF improvement > 35% between Days 90 and 180 following guideline-recommended medical therapy initiation and the percentage of target dose reached at Days 90 and 180.

Results

A total of 598 patients with de novo HFrEF [59 years (

SUBMITTER: Veltmann C 

PROVIDER: S-EPMC11313580 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature